A detailed history of 17 Capital Partners, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, 17 Capital Partners, LLC holds 5,846 shares of NBIX stock, worth $734,549. This represents 0.44% of its overall portfolio holdings.

Number of Shares
5,846
Previous 2,965 97.17%
Holding current value
$734,549
Previous $408,000 64.95%
% of portfolio
0.44%
Previous 0.29%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$114.58 - $153.15 $330,104 - $441,225
2,881 Added 97.17%
5,846 $673,000
Q2 2024

Jul 18, 2024

BUY
$130.86 - $143.19 $387,999 - $424,558
2,965 New
2,965 $408,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track 17 Capital Partners, LLC Portfolio

Follow 17 Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of 17 Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on 17 Capital Partners, LLC with notifications on news.